Several other analysts also recently weighed in on the company. Numis Securities restated a buy rating and set a GBX 1,275 ($16.66) target price on shares of Clinigen Group in a research note on Wednesday, February 27th. Royal Bank of Canada restated a top pick rating and set a GBX 1,640 ($21.43) target price (up from GBX 1,470 ($19.21)) on shares of Clinigen Group in a research note on Wednesday, February 27th. Four research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of Buy and an average price target of GBX 1,325 ($17.31).
Shares of Clinigen Group stock opened at GBX 940.04 ($12.28) on Tuesday. The company has a debt-to-equity ratio of 56.71, a current ratio of 1.54 and a quick ratio of 1.32. The stock has a market cap of $1.25 billion and a PE ratio of 47.24. Clinigen Group has a 1-year low of GBX 716 ($9.36) and a 1-year high of GBX 1,054 ($13.77).
The company also recently declared a dividend, which will be paid on Friday, April 12th. Investors of record on Thursday, March 21st will be paid a GBX 1.95 ($0.03) dividend. The ex-dividend date is Thursday, March 21st. This represents a yield of 0.21%. Clinigen Group’s dividend payout ratio (DPR) is 0.30%.
About Clinigen Group
Clinigen Group plc operates as a specialty pharmaceutical and services company. The company operates through three segments: Commercial Medicines, Unlicensed Medicines, and Clinical Trial Services. The Commercial Medicines segment acquires and licenses commercial medicines and then revitalises them, as well as provides access to licensed and branded generic medicines in the Africa and Asia Pacific region.
See Also: Momentum Investing
Receive News & Ratings for Clinigen Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinigen Group and related companies with MarketBeat.com's FREE daily email newsletter.